Upgrade to SI Premium - Free Trial

Goldman Sachs Reiterates Neutral Rating on Gilead Sciences (GILD)

February 11, 2026 5:04 AM
Goldman Sachs analyst Salveen Richter reiterated a Neutral rating and $125.00 price target on Gilead Sciences (NASDAQ: GILD).The analyst comments ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments

Next Articles